Navigation Links
BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
Date:12/9/2011

hat XIAFLEX is approved for Dupuytren's contracture in the United States and Europe and is moving forward with multiple clinical trials for additional indications, BioSpecifics has major progress potential ahead and I look forward to contributing to its continued success," said Mr. Gould.

"We are delighted that George has joined our Board of Directors. He has sat on the board of a number of public pharmaceutical companies and was at Hoffmann-La Roche for 28 years as a Vice President in licensing and IP. I believe his experience and expertise will be invaluable to BioSpecifics as XIAFLEX advances toward approval in several new clinical indications," reflected Thomas Wegman, President of BioSpecifics.

Mr. Gould has served on the Board of Directors of Tapestry Pharmaceuticals, Supratek Pharma, AngioGenex and Protein Design Labs. Prior to his current work, he was Senior Vice President at Pharmagenics for 1 year and before that, he was Vice President of Licensing and Corporate Development and Chief Patent Counsel at Hoffmann-La Roche for 28 years. He was also a Senior Patent Attorney at Esso Research & Engineering Co. for 6 years and was an organic chemist at Merck. He holds a JD from Columbia University School of Law and a LLM from New York University School of Law. He received a BA in Organic Chemistry from The Johns Hopkins University.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... agreement with Novella Clinical (Novella), to conduct ... with newly diagnosed glioblastoma. Novella is a full-service, global ... small to mid-sized oncology companies. The ICT-107 phase 3 ... US, Europe and ...
(Date:7/3/2015)... Houston, Texas (PRWEB) , ... July 03, 2015 ... ... search firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically ... aimed to make clients laugh, honor a good cause and break from their ...
(Date:7/3/2015)... 3, 2015  Pomerantz LLP announces that a class ... ("Puma" or the "Company")(NYSE: PBYI ) and certain ... States District Court, Central District of California ... of a class consisting of all persons or entities ... May 13, 2015 inclusive (the "Class Period").  This class ...
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... Netherlands and LONDON, September 26 ,Nobilon International B.V., ... of Akzo Nobel, and Protherics PLC, the international ... announced that Nobilon,has licensed Protherics, CoVaccine HT(TM) adjuvant ... vaccines in elderly people. More than 300 ...
... 26th at 8:30am, NEW YORK, Sept. 25 ... it will conduct a conference call,to discuss a strategic ... a territory outside the US. The call will ... Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals,will ...
... Bone Innovations, Inc. (SBi),a single-source provider of products, technology ... introduced its PRECISE SD(TM) Volar Distal,Radius Locking Plate system ... SD plate geometry is based on computer analysis of ... in the Hamann Todd,Osteological Collection at the Cleveland Museum ...
Cached Biology Technology:Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 3Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance 2Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures 2Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures 3Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures 4
(Date:6/15/2015)... June 15, 2015 A new report ... reveals the majority of US consumers using mobile banking applications ... such as fingerprint and voiceprint, instead of having to prove ... to Telstra,s " Mobile Identity   -   The Fusion ... with smartphones now the primary channel used by Gen X ...
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... a common non-motor symptom of Parkinson,s disease whose ... with psychosis has been shown to induce injury ... cortical areas. Jingmei Zhong and colleagues from First ... diffusion tensor imaging study in parkinson,s disease patients ...
... Penn Medicine researcher is among the winners of ... fast track his lab,s work to stop drug-resistant bacteria. ... with, and as a result more than 2 million people ... least 23,000 people die as a direct result. With ...
... source of phytochemicals called polyphenols, which have been reported by ... of protective health benefits. A new study by researchers at ... evidence. This new research, published today in ... that regular long-term wild blueberry diets may help improve or ...
Cached Biology News:Targeting evolution: Could this be the next strategy to stop superbugs? 2Health benefits of wild blueberries abound: Study 2
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
...
...
Biology Products: